Levemir Flexpen

Insulin Detemir, the active ingredient in Levemir Flexpen, is a long‑acting insulin analog presented as an injectable solution for subcutaneous use. It provides basal insulin replacement to help lower blood glucose levels in individuals with type 1 and type 2 diabetes mellitus.

GNH USA supplies Levemir Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable cold‑chain logistics for this injectable product. The product is sourced from EU manufacturers and distributed under strict temperature‑controlled conditions.

Levemir Flexpen (Insulin Detemir) is used as basal insulin therapy to maintain stable glucose levels in diabetes. - Type 1 diabetes mellitus: provides long‑acting basal insulin to complement mealtime insulin and achieve target fasting glucose. - Type 2 diabetes mellitus: supplies basal insulin when oral agents are insufficient to control fasting glucose. - Other forms of diabetes requiring basal insulin support: offers consistent insulin coverage for conditions such as maturity‑onset diabetes of the young (MODY) or secondary diabetes.

Levemir Flexpen may be associated with several adverse reactions, ranging from frequent mild events to rare serious conditions. Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight with prolonged therapy. Serious or Rare Side Effects: - Severe hypoglycemia: can lead to seizures, loss of consciousness, or injury. - Allergic reactions including anaphylaxis: rash, urticaria, swelling, or life‑threatening systemic response. - Insulin antibodies: formation of antibodies that may alter insulin action or cause delayed reactions.

When using Levemir Flexpen, consider the following precautions to ensure safe and effective therapy. - Dose adjustment: individualize based on self‑monitoring of blood glucose and clinical response. - Renal impairment: use with caution and monitor glucose closely. - Hepatic impairment: consider reduced clearance and adjust dose as needed. - Pregnancy and lactation: evaluate risk‑benefit and monitor maternal glucose tightly. - Hypoglycemia risk: educate patients on recognizing and treating low glucose episodes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Flexpen can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes. Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms, requiring closer monitoring. - MAO inhibitors: can potentiate insulin’s glucose‑lowering effect, increasing hypoglycemia risk. - Alcohol: may enhance insulin action and precipitate severe hypoglycemia. Moderate Interactions (Monitor Closely): - Thiazide diuretics: may increase blood glucose, potentially reducing insulin effectiveness. - Corticosteroids: can raise glucose levels, necessitating dose adjustments. - ACE inhibitors: may affect potassium balance, requiring periodic electrolyte checks.